The mutation of PTPRD may influence CD4+ T cell infiltration via its phosphatase activity, and promote the occurrence of “hot” TME with enhanced anti-tumor immunity in advanced NSCLC patients. Here, PTPRD is linked to non-small cell lung carcinoma.